Teleflex (NYSE:TFX) Stock Rating Lowered by Wall Street Zen

Teleflex (NYSE:TFX) was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Sunday.

Several other equities analysts also recently commented on TFX. Mizuho set a $155.00 price target on shares of Teleflex in a research note on Wednesday, April 16th. Bank of America downgraded shares of Teleflex from a “neutral” rating to an “underperform” rating and reduced their price objective for the stock from $235.00 to $140.00 in a research note on Tuesday, March 4th. Truist Financial reduced their price objective on shares of Teleflex from $140.00 to $137.00 and set a “hold” rating on the stock in a research note on Monday, May 5th. Wells Fargo & Company reduced their price objective on shares of Teleflex from $146.00 to $137.00 and set an “equal weight” rating on the stock in a research note on Friday, May 2nd. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Teleflex in a research note on Wednesday, March 12th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Teleflex has a consensus rating of “Hold” and a consensus target price of $164.63.

Teleflex Trading Down 0.1%

TFX stock opened at $119.42 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.32 and a current ratio of 2.28. The company’s 50-day simple moving average is $124.41 and its 200 day simple moving average is $147.58. Teleflex has a 52 week low of $115.94 and a 52 week high of $249.91. The company has a market capitalization of $5.28 billion, a PE ratio of 37.67, a price-to-earnings-growth ratio of 1.87 and a beta of 1.10.

Teleflex (NYSE:TFX) last released its quarterly earnings results on Thursday, May 1st. The medical technology company reported $2.91 EPS for the quarter, beating the consensus estimate of $2.88 by $0.03. Teleflex had a net margin of 4.96% and a return on equity of 14.73%. The business had revenue of $700.67 million for the quarter, compared to the consensus estimate of $699.37 million. During the same period in the prior year, the company posted $3.21 earnings per share. Teleflex’s revenue was down 5.0% compared to the same quarter last year. As a group, sell-side analysts anticipate that Teleflex will post 13.98 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in TFX. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Teleflex by 103.1% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 197 shares of the medical technology company’s stock worth $27,000 after acquiring an additional 100 shares during the last quarter. Banque Cantonale Vaudoise bought a new position in shares of Teleflex in the first quarter worth about $27,000. Costello Asset Management INC bought a new position in shares of Teleflex in the first quarter worth about $28,000. Headlands Technologies LLC bought a new position in shares of Teleflex in the fourth quarter worth about $29,000. Finally, Brooklyn Investment Group lifted its holdings in shares of Teleflex by 258.6% in the first quarter. Brooklyn Investment Group now owns 208 shares of the medical technology company’s stock worth $29,000 after acquiring an additional 150 shares during the last quarter. Institutional investors own 95.62% of the company’s stock.

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications worldwide. The company provides vascular access products that comprise Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous access systems for the administration of intravenous therapies, the measurement of blood pressure, and the withdrawal of blood samples through a single puncture site.